Skin Toxicity Program Can Positively Address EGFR Inhibitor-Related Skin Toxicities
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
All articles by Leah Lawrence
Model Could Help Identify Who May Respond to Checkpoint Inhibition in Melanoma
Imaging radiomics and blood markers could differentiate pseudoprogression.
Minority of Melanomas With Complete Response to Anti–PD-1 Relapsed After Drug Cessation
More research is needed to define criteria for stopping therapy.
Advanced Melanoma May Benefit From Encorafenib, Binimetinib Combination
The FDA accepted a New Drug Application to support the combination of the MEK inhibitor, binimetinib, and the BRAF inhibitor, encorafenib, for treating patients with BRAF-mutated unresectable or metastatic melanoma.
Preventing Melanoma With Nicotinamide: Yes or No?
Nicotinamide, a form of vitamin B3 (niacin), is a “promising and well-tolerated” chemopreventive agent for patients at high risk for developing skin cancer, according to the results of a recent review of the agent
-
Loading...
-
Loading...
Next post in Skin Cancer
